CL2016001209A1 - Agentes anticancerosos y sus preparaciones - Google Patents

Agentes anticancerosos y sus preparaciones

Info

Publication number
CL2016001209A1
CL2016001209A1 CL2016001209A CL2016001209A CL2016001209A1 CL 2016001209 A1 CL2016001209 A1 CL 2016001209A1 CL 2016001209 A CL2016001209 A CL 2016001209A CL 2016001209 A CL2016001209 A CL 2016001209A CL 2016001209 A1 CL2016001209 A1 CL 2016001209A1
Authority
CL
Chile
Prior art keywords
preparations
anticancer agents
anticancer
agents
Prior art date
Application number
CL2016001209A
Other languages
English (en)
Spanish (es)
Inventor
Arun K Ghosh
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of CL2016001209A1 publication Critical patent/CL2016001209A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CL2016001209A 2013-11-19 2016-05-19 Agentes anticancerosos y sus preparaciones CL2016001209A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361906133P 2013-11-19 2013-11-19

Publications (1)

Publication Number Publication Date
CL2016001209A1 true CL2016001209A1 (es) 2017-06-02

Family

ID=53180106

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001209A CL2016001209A1 (es) 2013-11-19 2016-05-19 Agentes anticancerosos y sus preparaciones

Country Status (20)

Country Link
US (1) US10000505B2 (enExample)
EP (1) EP3071563B1 (enExample)
JP (2) JP6937578B2 (enExample)
KR (1) KR102428737B1 (enExample)
CN (3) CN105829299A (enExample)
AU (1) AU2014353087B2 (enExample)
BR (1) BR112016011430B1 (enExample)
CA (1) CA2931111C (enExample)
CL (1) CL2016001209A1 (enExample)
DK (1) DK3071563T3 (enExample)
EA (1) EA035262B1 (enExample)
ES (1) ES2943711T3 (enExample)
FI (1) FI3071563T3 (enExample)
IL (2) IL282430B2 (enExample)
MX (1) MX375896B (enExample)
MY (1) MY189459A (enExample)
PE (1) PE20161240A1 (enExample)
PH (2) PH12021551085A1 (enExample)
PT (1) PT3071563T (enExample)
WO (1) WO2015077370A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10000505B2 (en) 2013-11-19 2018-06-19 Purdue Research Foundation Anti-cancer agents and preparation thereof
EP3468976A4 (en) * 2016-06-08 2019-11-27 William Marsh Rice University DERIVATIVES OF THAILANSTATIN A, METHOD FOR THE TREATMENT AND METHOD FOR SYNTHESIS THEREOF
AU2017331260B2 (en) * 2016-09-23 2024-11-07 Purdue Research Foundation Anti-cancer agents and preparation thereof
ES3075078T3 (es) 2017-09-20 2026-07-27 Ph Pharma Co Ltd Análogos de tailanstatina
CN109020876A (zh) * 2018-09-21 2018-12-18 大连理工大学 一种新型6-羟基-2h-二氢吡啶-3-酮的制备方法
CN120189526A (zh) 2018-12-13 2025-06-24 卫材R&D管理有限公司 荷伯希二烯抗体-药物缀合物及使用方法
WO2021207511A1 (en) * 2020-04-09 2021-10-14 Bristol-Myers Squibb Company Meayamycin analogues and methods of use
CN113563361B (zh) * 2021-08-17 2022-05-20 浙江珲达生物科技有限公司 一种从伯克霍尔德菌发酵液提取fr901464的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901464A (fr) 1943-01-23 1945-07-27 Boehringer & Soehne Gmbh Procédé d'obtention de vanilline
US7825267B2 (en) * 2006-09-08 2010-11-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Synthesis of FR901464 and analogs with antitumor activity
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
AR080234A1 (es) * 2010-02-25 2012-03-21 Marrone Bio Innovations Inc Cepa bacteriana aislada del genero burkholderia y metabolitos pesticidas del mismo
EP2748304A4 (en) * 2011-08-27 2015-02-11 Marrone Bio Innovations Inc ISOLATED BACTERIAL STRUCTURE OF STRAIN BURKHOLDERIA, PESTICIDE METABOLITE THEREOF, AND FORMULATIONS AND USES THEREOF
MX340090B (es) 2012-11-05 2016-06-23 Pfizer Analogos de spliceostatina.
US10000505B2 (en) 2013-11-19 2018-06-19 Purdue Research Foundation Anti-cancer agents and preparation thereof

Also Published As

Publication number Publication date
JP2017503753A (ja) 2017-02-02
JP2019189644A (ja) 2019-10-31
EA201691010A1 (ru) 2016-11-30
US20160297831A1 (en) 2016-10-13
WO2015077370A1 (en) 2015-05-28
EP3071563A1 (en) 2016-09-28
PH12021551085A1 (en) 2023-07-17
BR112016011430A2 (pt) 2017-09-12
US10000505B2 (en) 2018-06-19
JP6937578B2 (ja) 2021-09-22
CN113461705A (zh) 2021-10-01
CA2931111C (en) 2022-03-15
IL245637A0 (en) 2016-06-30
AU2014353087B2 (en) 2018-07-19
CN113773333A (zh) 2021-12-10
EP3071563A4 (en) 2017-09-06
PT3071563T (pt) 2023-05-09
MY189459A (en) 2022-02-14
MX375896B (es) 2025-03-07
AU2014353087A1 (en) 2016-06-30
KR102428737B1 (ko) 2022-08-02
CN105829299A (zh) 2016-08-03
IL282430A (en) 2021-06-30
IL245637B (en) 2021-05-31
NZ721152A (en) 2022-03-25
CA2931111A1 (en) 2015-05-28
IL282430B2 (en) 2025-04-01
ES2943711T3 (es) 2023-06-15
BR112016011430B1 (pt) 2022-09-13
IL282430B1 (en) 2024-12-01
PH12016500924A1 (en) 2016-07-18
PE20161240A1 (es) 2016-11-27
JP6929903B2 (ja) 2021-09-01
MX2016006591A (es) 2017-05-30
FI3071563T3 (fi) 2023-05-29
EP3071563B1 (en) 2023-04-19
DK3071563T3 (da) 2023-05-08
NZ759166A (en) 2022-03-25
KR20160086411A (ko) 2016-07-19
EA035262B1 (ru) 2020-05-21

Similar Documents

Publication Publication Date Title
CL2016000981A1 (es) Formulaciones de estrigolactona y sus usos
IL247262B (en) Cannabinoid compositions and uses
HRP20181580T1 (hr) Pripravci cftr irnk i povezani postupci i upotrebe
UA27744S (uk) Інтерфейс графічний
UA27432S (uk) Інтерфейс графічний
UA27427S (uk) Інтерфейс графічний
UA27429S (uk) Інтерфейс графічний
UA27423S (uk) Інтерфейс графічний
UA27442S (uk) Інтерфейс графічний
UA27732S (uk) Інтерфейс графічний
UA27422S (uk) Інтерфейс графічний
UA27435S (uk) Інтерфейс графічний
UA27425S (uk) Інтерфейс графічний
UA27421S (uk) Інтерфейс графічний
UA27417S (uk) Інтерфейс графічний
UA27439S (uk) Інтерфейс графічний
UA27419S (uk) Інтерфейс графічний
UA28436S (uk) Інтерфейс графічний
UA27441S (uk) Інтерфейс графічний
UA27418S (uk) Інтерфейс графічний
UA27443S (uk) Інтерфейс графічний
UA27722S (uk) Інтерфейс графічний
PL2970267T6 (pl) Modulatory P2X7
UA27424S (uk) Інтерфейс графічний
EP2953792A4 (en) Graphic article